Kadcyla and Ranitidine drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Kadcyla (ado-trastuzumab emtansine) and Ranitidine (ranitidine). Common drug interactions include cardiac failure among females and bacteraemia among males.

The phase IV clinical study analyzes what interactions people have when they take Kadcyla and Ranitidine. It is created by eHealthMe based on reports of 38 people who take the same drugs from the FDA, and is updated regularly.

What is Kadcyla?

Kadcyla has active ingredients of ado-trastuzumab emtansine. eHealthMe is studying from 5,813 Kadcyla users. Check the latest studies of Kadcyla.

What is Ranitidine?

Ranitidine has active ingredients of ranitidine. It is often used in gastroesophageal reflux disease. eHealthMe is studying from 234,475 Ranitidine users. Check the latest studies of Ranitidine.

On Jul, 10, 2026

38 people who take Kadcyla and Ranitidine together, and have interactions are studied.

Kadcyla and Ranitidine drug interactions.

What are the common drug interactions of Kadcyla and Ranitidine, by gender? *:

female:

Cardiac failure
Hypertrophic cardiomyopathy (a condition in which the heart muscle becomes abnormally thick)
Epistaxis (bleed from the nose)
Vitamin d deficiency
Alanine aminotransferase increased
Aspartate aminotransferase increased
Diarrhoea
Blood bilirubin increased
Performance status decreased
Nausea (feeling of having an urge to vomit)

male:

Bacteraemia (presence of bacteria in the blood)
Dizziness
Febrile neutropenia (fever with reduced white blood cells)
Headache (pain in head)
Malignant neoplasm progression (cancer tumour came back)
Muscular weakness (muscle weakness)
Skin cancer

What are the common drug interactions of Kadcyla and Ranitidine, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

Bacteraemia (presence of bacteria in the blood)
Dizziness
Febrile neutropenia (fever with reduced white blood cells)
Headache (pain in head)
Malignant neoplasm progression (cancer tumour came back)
Muscular weakness (muscle weakness)
Pulmonary embolism (blockage of the main artery of the lung)
Skin cancer

40-49:

Mean cell volume increased (more than normal average red blood cell volume)
Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)
Neutrophil count increased (excess than normal number of neutrophil a type of blood cell)
Platelet count decreased
Protein total decreased
Red blood cell count decreased
White blood cell count decreased
Hypertransaminasaemia
Metastases to central nervous system (cancer spreads to central nervous system)
Alanine aminotransferase increased

50-59:

Cough
Weight decreased
Pulmonary oedema (fluid accumulation in the lungs)
Blood cholesterol increased
Disease progression
Drug intolerance (drug sensitivity)
Haemorrhage (bleeding)
Hepatitis (inflammation of the liver)
Hepatotoxicity (chemical-driven liver damage)
Inflammation

60+:

Thrombocytopenia (decrease of platelets in blood)
Palmar-plantar erythrodysaesthesia syndrome (hand-foot syndrome)
Diarrhoea
Performance status decreased
Hypocalcaemia (levels of calcium in blood serum are abnormally low)
Nausea (feeling of having an urge to vomit)
Dysaesthesia (abnormal sensation)
Dysgeusia (disorder of the sense of taste)
Dysphagia (a condition in which swallowing is difficult or painful)
Skin toxicity (skin damage due to toxin/poison)

What are the existing conditions these people have? *

Breast Cancer: 15 people, 39.47%
Breast Cancer Metastatic: 10 people, 26.32%
Hypertensive Crisis: 7 people, 18.42%
Thrombosis (formation of a blood clot inside a blood vessel): 6 people, 15.79%
Rickets (softening of bones): 6 people, 15.79%
High Blood Pressure: 6 people, 15.79%
Skin Toxicity (skin damage due to toxin/poison): 4 people, 10.53%
Nausea (feeling of having an urge to vomit): 3 people, 7.89%
Taste - Impaired: 2 people, 5.26%
Swallowing Difficulty: 2 people, 5.26%

* Approximation only. Some reports may have incomplete information.

Do you take Kadcyla and Ranitidine?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously